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Coronavirus disease 2019 (COVID-19) is a recently described infectious disease caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since late 2019,
COVID-19 has rapidly spread in virtually all countries, imposing the adoption of significant
lockdown and social distancing measures. The activation of the coagulation cascade
is a common feature of disseminated intravascular coagulation and adverse clinical
outcomes in COVID-19 patients. In this study, we conducted a meta-analysis aiming
to investigate differences in serum D-dimer concentrations in patients with and without
severe COVID-19 disease. An electronic search in Medline (PubMed), Scopus and Web
of Science was performedwith no language restrictions, and 13 articles were reporting on
1,807 patients (585, 32.4% with severe disease) were finally identified and included in the
meta-analysis. The pooled results of all studies revealed that the D-dimer concentrations
were significantly higher in patients with more severe COVID-19 (SMD: 0.91 mg/L; 95%
CI, 0.75 to 1.07 mg/L, p < 0.0001). The heterogeneity was moderate (I2 = 46.5%;
p = 0.033). Sensitivity analysis showed that the effect size was not modified when any
single study was in turn removed (effect size range, 0.87mg/L to 0.93mg/L). The Begg’s
(p = 0.76) and Egger’s tests (p = 0.38) showed no publication bias. In conclusion,
our systematic review and meta-analysis showed that serum D-dimer concentrations
in patients with severe COVID-19 are significantly higher when compared to those with
non-severe forms.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a recently described infectious disease caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Since late 2019,
COVID-19 has rapidly spread in virtually all countries, affecting more than two million
people and causing more than 150,000 deaths worldwide (data from 17 Apr 2020, https://
www.worldometers.info/coronavirus/). These figures are continuously growing despite the
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adoption of significant lockdown and social distancing measures,
particularly in Eastern Asia, Europe, and North America (2).
The rapid expansion and the relatively high lethality may
depend on several biological characteristics, such as the high
infectivity of SARS-CoV-2, the high percentage of asymptomatic
vectors, and the relatively long incubation period (3). However,
significant knowledge gaps remain in the pathophysiology of
the disease. In this context, a better knowledge of the factors
that are responsible for the development of significant clinical
complications in a subgroup of COVID-19 patients, indicating
high disease severity, might lead to the identification of better
pharmacological and non-pharmacological therapies and care
pathways. This would improve patient outcomes, and reduce the
current burden on health care systems, pending the development
of effective vaccines. There is increasing evidence that SARS-
CoV-2 induces, in severe cases, a cytokine storm that triggers
the coagulation cascade, causing thrombotic complications (4).
This is clinically relevant as the activation of the coagulation
cascade is a common feature of disseminated intravascular
coagulation (DIC) and adverse clinical outcomes in COVID-
19 patients and appears to be more frequent than what
observed in patients suffering from severe forms of SARS-
CoV in 2003 (5). The key pathophysiological role of DIC
in the clinical progress of COVID-19 is further supported
by the presence, in autopsies of patients succumbing to the
disease, of fibrinous thrombi, endothelial tumefaction, and
megakaryocytes in small pulmonary arteries and pulmonary
capillaries (6).
The D-dimer, a fibrin degradation product, is a relatively
small protein fragment that is present in the blood following
degradation of blood clots by fibrinolysis. The determination of
circulating D-dimer concentrations is a sensitive test in clinical
practice to diagnose thrombotic states, including pulmonary
embolism and DIC (7). Therefore, elevations in D-dimer levels in
COVID-19 patientsmight be helpful to rapidly identify those that
have high disease severity, pulmonary complications, and risk
of venous thromboembolism in the setting of a pro-thrombotic
state. This would assist with risk stratification and the early
introduction of therapeutic measures that might reduce COVID-
19 related morbidity and mortality.
A recent meta-analysis has shown that patients with severe
forms of COVID-19 have higher D-dimer concentrations when
compared to those with milder forms (8). However, only a
small number of studies in a total of 553 patients were selected.
Furthermore, in this meta-analysis the heterogeneity across the
studies was extremely high, I2 94%, P < 0.001). Therefore, we
conducted an updated meta-analysis that takes into account
additional studies to investigate differences in serum D-dimer
concentrations in patients with and without severe COVID-
19 disease.
MATERIALS AND METHODS
Study Search and Selection
An electronic search in Medline (PubMed interface), Scopus,
and Web of Science was performed using the keywords “D-
dimer” AND “coronavirus” OR “D-dimer” AND “COVID-19.”
The inclusion criteria were: (a) studies reporting continuous
data on serum D-dimer concentrations in COVID-19 patients,
(b) articles dividing COVID-19 patients in severity classes, (c)
articles including adult patients, (d) studies approved by an
ethical committee, and (e) articles published from 1st January
2020 to the date of the electronic search (14th April, 2020).
There were no language restrictions. The titles, abstracts and
full texts of the publications retrieved were screened by two
independent investigators (PP and AZ). The reference list of the
studies identified was also checked in order to identify additional
studies. The Newcastle—Ottava Scale (NOS) was used for quality
assesment. This meta-analysis was conducted according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Supplementary Materials).
Statistical Analysis
Standardized mean differences (SMD) were used to build forest
plots of continuous data and to evaluate differences in serum
D-dimer concentrations between severe and non-severe patients
with COVID-19 disease. A P-value < 0.05 was considered
statistically significant, and 95% confidence intervals (CIs) were
reported. When necessary, the mean and standard deviation
values were extrapolated from median and IQR values, as
previously reported by Wan et al. (9). Heterogeneity of SMD
FIGURE 1 | Flow-chart illustrating the electronic search strategy and results.
Frontiers in Public Health | www.frontiersin.org 2 August 2020 | Volume 8 | Article 432
Paliogiannis et al. D-Dimer and COVID-19 Severity
TABLE 1 | Characteristics of the patients and D-dimer values in the studies enrolled for meta-analysis.
References NOS stars Total cases
(severe)
Age Males, n (%) D-dimer total
(mg/L)
D-dimer severe
(mg/L)
D-dimer
non-severe (mg/L)
Zhou et al. (16) 6 17 (5) NA 6 (35) NA 0.28 ± 0.11 0.29 ± 0.11
Tang et al. (17) 7 449 (134) 65 (mean) 268 1.94 (0.90–9.44) 4.70 (1.42–21.00) 1.47 (0.78–4.16)
Chen et al. (18) 6 21 (11) 56 (median) 17 (81) 0.5 (0.4–1.8) 2.6 (0.6–18.7) 0.3 (0.3–0.4)
Chen et al. (19) 6 274 (113) 62 (median) 171 (62) 1.1 (0.5–3.2) 4.6 (1.3–21.0) 0.6 (0.3–1.3)
Wan et al. (20) 6 135 (40) 47 (median) 72 (53) 0.4 (0.2–0.6) 0.6 (0.4–1.1) 0.3 (0.2–0.5)
Gao et al. (21) 6 43 (15) 45 (mean) 26 (58) NA 0.49 (0.29-0.91) 0.21 (0.19–0.27)
Han et al. (22) 6 84 (35) NA NA NA 19.11 ± 35.48 2.14 ± 2.88
Zhou et al. (23) 7 191 (54) 56 (median) 119 (62) 0.8 (0.4–3.2) 5.2 (1.5–21.1) 0.6 (0.3–1.0)
Wu et al. (24) 6 201 (84) 51 (median) 128 (64) 0.61 (0.35–1.28) 1.16 (0.46–5.37) 0.52 (0.33–0.93)
Liu et al. (25) 6 30 (4) 35 (mean) 10 (33) NA 1.54 ± 1.22 0.26 ± 0.08
Zhang et al. (26) 7 138 (56) 57 (median) 71 (51) 0.2 (0.1–0.5) 0.4 (0.2–2.4) 0.2 (0.1–0.3)
Tang et al. (27) 7 183 (21) 54 (mean) 98 (53) 0.66 (0.38–1.50) 2.12 (0.77–5.27) 0.61 (0.35–1.29)
Huang et al. (28) 7 41 (13) 49 (median) 30 (73) 0.5 (0.3–1.3) 2.4 (0.6–14.4) 0.5 (0.3–0.8)
Total 1,807 (585)
NOS, Newcastle – Ottawa Scale; NA, not available.
across studies was tested using the Q statistic (significance level at
p< 0.10). The I2 statistic, a quantitative measure of inconsistency
across studies, was also calculated (I2 < 25%, no heterogeneity; I2
between 25 and 50%, moderate heterogeneity; I2 between 50 and
75%, large heterogeneity; and I2 > 75%, extreme heterogeneity)
(10, 11). In analyses in which heterogeneity was high, a random-
effects model was applied. To investigate the influence of an
individual study on the overall risk estimate, a sensitivity analysis
was conducted by sequentially excluding one study at a time
(12). Begg’s adjusted rank correlation test and Egger’s regression
asymmetry test, for the analysis of associations between study
size and magnitude of effect were used to evaluate the presence
of potential publication bias (13, 14). The Duval and Tweedie
“trim and fill” procedure to identify and correct for funnel plot
asymmetry arising from publication bias was also used (15).
Statistical analyses were performed using Stata 14 (STATA Corp.,
College Station, TX, USA).
RESULTS
Study Selection Results and
Characteristics
The flow diagram of the literature search performed is presented
in Figure 1. From an initial total of 69 studies, 13 were finally
identified and included in the meta-analysis (16–28); the total
number of COVID-19 patients in these studies was 1,807.
Among them, 585 (32.4%) were affected by a severe form of
COVID-19 (Table 1). The NOS quality assessment is described
in Table 1.
All selected studies were conducted in China. Six articles
defined severe cases based on current clinical guidelines (20–
22, 24–26), four defined severe cases as those who died in
comparison to survivors (17, 19, 23, 27), and three had alternative
definitions (disease progression vs. no progression or admission
vs. no admission to intensive care units) (16, 18, 28).
Meta-Analysis
The mean differences in serum D-dimer concentrations between
COVID-19 patients with or without severe disease in the 13
studies are shown in Figure 2. In 12 studies, patients with severe
COVID-19 displayed higher D-dimer serum concentrations
when compared to those with milder forms (mean difference
range, 0.62–3.15 mg/L) (17–28). By contrast, in the remaining
study, the D-dimer concentration was found to be mildly higher
in patients with non-severe forms of COVID-19 (mean difference
0.09 mg/L) (16). The pooled results of all studies revealed that
the D-dimer concentrations were significantly higher in patients
with more severe COVID-19 (SMD: 0.91 mg/L; 95% CI, 0.75 to
1.07 mg/L, p < 0.0001). The heterogeneity was moderate (I2 =
46.5%; p = 0.033). Sensitivity analysis showed that the effect size
was not modified when any single study was in turn removed
(effect size range, 0.87 mg/L−0.93 mg/L, Figure 3). The Begg’s
(p = 0.76) and Egger’s tests (p = 0.38) showed no publication
bias. Accordingly, the trim-and-fill analysis found that no study
was missing or should be added (Figure 4). In meta-regression
analysis, no correlation was found either between SMD and age
(p = 0.37) or between SMD and gender (p = 0.41). Notably, the
age ratio between patients withmore severe COVID-19 and those
with milder forms was relatively small, between 1.0 and 1.3, in
all studies. In addition, as reported in Figure 5, there were no
significant differences in SMD values between the subgroup of
patients classified according to guidelines (SMD: 0.94 mg/L; 95%
CI 0.78 to 1.10 mg/L, p < 0.0001) and the subgroup classified as
dead or survivors (SMD: 0.97 mg/L; 95% CI 0.65 to 1.29 mg/L,
p < 0.0001), although in the first group a significantly lower
heterogeneity was observed (I2 = 21.4%, p < 0.28 vs. I2 = 65.5%,
p < 0.013).
DISCUSSION
Our updated meta-analysis of 13 studies in 1,807 COVID-
19 patients showed that the serum D-dimer concentrations in
Frontiers in Public Health | www.frontiersin.org 3 August 2020 | Volume 8 | Article 432
Paliogiannis et al. D-Dimer and COVID-19 Severity
FIGURE 2 | Forest plot illustrating D-dimer standardized mean differences (SMD) in patients with and without severe COVID-19.
patients with severe forms of the disease were significantly higher
than those in patients with milder forms. When compared
to a recent meta-analysis of four studies in a total of 553
COVID-19 patients, the observed SMD values were relatively
small, 0.91 mg/L (3, 17, 27, 28). Furthermore, in our meta-
analysis the heterogeneity was substantially lower, I2 46.5 vs.
94% (8). These results further support the presence of a pro-
thrombotic state, and possibly DIC, in COVID-19 patients
with severe disease, potentially accounting for the structural
and functional lung abnormalities commonly reported in this
subgroup. In support of this hypothesis, recent autoptic reports
have shown alterations compatible with DIC in the lungs
of COVID-19 patients (6). Interestingly, we observed no
significant associations between increasing SMD values and
the age ratio between patients with more severe COVID-
19 and those with milder forms, despite the established age-
related increase in serum D-dimer concentrations (7). As
patients with severe COVID-19 disease are also significantly
older than subgroups with milder forms (29), our findings
suggest that the reported differences in serum D-dimer
concentrations are independent of age differences in patients
with different disease severity. Although this further supports the
presence of DIC as the primary marker of D-dimer elevations
and COVID-19 severity, additional studies in cohorts with
higher age ratios between patients with more severe COVID-
19 and those with milder forms are required to confirm
this proposition.
Pending further research to investigate the cause-effect
relationship between serum D-dimer concentrations, COVID-
19 disease severity, the onset of pulmonary complications and
clinical outcomes, the identification of D-dimer as a biomarker
of COVID-19 severity is potentially clinically relevant. Its
relatively simple and inexpensive determination might assist,
particularly with serial assessments, with the rapid identification
of those patients developing DIC, pulmonary compromise, or
at risk of venous thromboembolism that requires aggressive
care and intensive monitoring (30). While the development of
COVID-19 vaccines is eagerly awaited, a better understanding of
the pathophysiological mechanisms responsible for the clinical
deterioration and increased risk of death in affected patients
is likely to be beneficial. For example, the rapid initiation
of DIC therapies, instigated by high D-dimer concentrations
and the presence of other diagnostic criteria, might provide
additional therapeutic advantages in severe COVID-19 patients
already receiving ventilatory and circulatory support (30). This
proposition is supported by the findings of a recent study in
449 severe COVID-19 patients with significant elevations of
serum D-dimer concentrations and/or criteria for DIC. The
administration of low molecular weight heparin in these patients
was associated with a significant improvement in 28-day survival
when compared to non-users (27).
The moderate heterogeneity in the studies enrolled might
depend on the different definitions of disease severity; in
six studies, available clinical guidelines were followed, mainly
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FIGURE 3 | Sensitivity analysis of the studies enrolled. CI, confidence interval.
FIGURE 4 | Trim-and-fill analysis of the studies enrolled.
the “new coronavirus pneumonia diagnosis and treatment
plan” (versions 4 and 5) developed by the National Health
Committee of the People’s Republic of China (31). In four
studies, the severity of the disease was based on survivorship
or death, and finally, in the remaining three studies, further
classifications were used, such as disease progression vs. no
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FIGURE 5 | Forest plots illustrating subgroup analyses on the basis of the definition of COVID-19 severity. SMD: standardized mean difference.
progression, and admission or no admission in intensive
care units. For this reason, we performed subgroup analyses,
which showed no significant differences in SMD values
between the subgroup of patients classified according to clinical
guidelines and the subgroup classified as dead or survivors.
Further potential issues are that all the included studies were
carried out in China, no strict diagnostic performance was
investigated, and no specific guidelines for reporting (such
as the Standards for Reporting Diagnostic Accuracy Studies,
STARD recommendations) were followed in each individual
study. Other potential sources of heterogeneity, not described
in the identified studies, include differences in the timing
of blood sample collection and analytical protocols for D-
dimer measurement.
In conclusion, our systematic review and meta-analysis
showed that the serum concentrations of D-dimer, a fibrin
degradation product that is used to diagnose the presence of
a pro-thrombotic state, are significantly higher in patients with
severe COVID-19 when compared to those with non-severe
forms. This suggests that D-dimer concentrations might be
helpful to rapidly identify COVID-19 patients with high risk
of pulmonary complications and venous thromboembolism,
facilitating the early initiation of effective therapies. However,
further studies are required to confirm such findings in different
geographical areas, using robust assessment methods, and to
investigate the associations between D-dimer concentrations,
COVID-19 disease progress, response to treatment, and overall
clinical prognosis.
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